WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

Cardio drugmaker Kardigan plans to go public

Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.

Raccontata dabiopharmadive.comendpoints.newspharmaceutical-technology.com

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
biopharmadive.comStai leggendo21 h fa

Cardio drugmaker Kardigan plans to go public

Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.

originale
pharmaceutical-technology.com7 h fa

Kardigan targets IPO to support cardiology pipeline progression - Pharmaceutical Technology

Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline.

Leggi questa versione → originale
endpoints.news21 h fa

Kardigan readies Nasdaq IPO to back three cardio drugs

Cardiology biotech Kardigan filed for a Nasdaq IPO under ticker {$KARD}, joining a growing roster of clinical-stage drug developers tapping reopened capital markets.

Leggi questa versione → originale

Timeline cronologica

  1. mercoledì 27 maggio 2026·biopharmadive.com

    Cardio drugmaker Kardigan plans to go public

    Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.

  2. mercoledì 27 maggio 2026·endpoints.news

    Kardigan readies Nasdaq IPO to back three cardio drugs

    Cardiology biotech Kardigan filed for a Nasdaq IPO under ticker {$KARD}, joining a growing roster of clinical-stage drug developers tapping reopened capital markets.

  3. mercoledì 27 maggio 2026·pharmaceutical-technology.com

    Kardigan targets IPO to support cardiology pipeline progression - Pharmaceutical Technology

    Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline.